Table 1.
Variable | Whole cohort (N = 126) | Uncontrolled (N = 16) | Unstable control (N = 29) | Controlled (N = 81) | P-value |
---|---|---|---|---|---|
Baseline characteristics | |||||
Age (years), median [IQ] | 66 [58–72] | 71 [61–76.5] | 69 [66–77] | 63 [55–70] | 0.003a |
Male, n (%) | 47 (37.30) | 9 (56.25) | 8 (27.59) | 30 (37.04) | 0.163b |
BMI (kg/m2), median [IQ] | 26.31 [23.89–28.76] | 28.30 [24.26–31.56] | 26.96 [25.00–30.19] | 26.03 [23.51–28.09] | 0.101a |
Reference systolic BP, mean (SD) | 124.78 (9.90) | 137.91 (11.14) | 128.31 (8.97) | 120.93 (6.91) | <.0001c |
Reference diastolic BP, mean (SD) | 76.19 (8.10) | 85.61 (7.31) | 76.98 (8.66) | 74.04 (6.59) | <.0001c |
Smokers, n (%) | 27 (21.43) | 8 (50.00) | 8 (27.59) | 11 (13.58) | 0.003 b |
Type II diabetes, n (%) | 23 (18.25) | 2 (12.50) | 7 (24.14) | 14 (17.28) | 0.583b |
Dyslipidaemia, n (%) | 47 (37.30) | 8 (50) | 16 (55.17) | 23 (28.40) | 0.020b |
Previous cardiovascular events, n (%) | 19 (15.08) | 3 (18.75) | 5 (17.24) | 11 (13.58) | 0.810d |
CCB, n (%) | 52 (57.14) | 9 (64.29) | 14 (56.00) | 29 (55.77) | 0.841b |
Beta-blockers, n (%) | 31 (34.07) | 6 (42.86) | 7 (28.00) | 18 (34.62) | 0.638b |
Diuretics, n (%) | 39 (42.86) | 7 (50.00) | 14 (56.00) | 18 (34.62) | 0.174b |
ACE inhibitors, n (%) | 25 (27.45) | 1 (7.14) | 9 (36.00) | 15 (28.85) | 0.145b |
ARB, n (%) | 44 (48.35) | 10 (71.43) | 11 (44.00) | 23 (44.23) | 0.194d |
Alpha-blockers, n (%) | 12 (13.19) | 1 (7.14) | 6 (24.00) | 5 (9.62) | 0.217d |
Number of drugs, n (%) | |||||
1 | 25 (27.47) | 1 (7.14) | 8 (32.00) | 16 (30.77) | 0.072d |
2 | 32 (35.16) | 8 (57.14) | 4 (16.00) | 20 (38.46) | |
3 | 22 (24.18) | 3 (21.43) | 7 (28.00) | 12 (23.08) | |
4 | 12 (13.19) | 2 (14.29) | 6 (24.00) | 4 (7.69) |
ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; IQ, interquartile range; SD, standard deviation.
Kruskal–Wallis.
Chi-square test.
ANOVA.
Fisher test.